Predict your next investment

Private Equity
auventx.com

See what CB Insights has to offer

Investments

12

Portfolio Exits

4

Partners & Customers

4

About Auven Therapeutics

Auven Therapeutics, formerly Celtic Therapeutics, is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets. Auven Therapeutics' business model addresses a market opportunity that bridges the gap between the lack of funding and often limited development expertise in small biotechnology companies and the shortage of late stage clinical products in established pharmaceutical companies' pipelines.

Auven Therapeutics Headquarter Location

6501 Redhook Plaza Suite 201

St. Thomas, 00802,

Virgin Islands (U.S.)

340-779-6908

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Auven Therapeutics News

Sarcoidosis Therapeutics Market Research Report 2022 – Global Forecast till 2027

Jan 18, 2022

Sarcoidosis Therapeutics Market Research Report 2022 – Global Forecast till 2027 Sarcoidosis also known as Besnier-Boeck-Schaumann disease is an inflammatory disease characterized by formation of garnulomas. The autoagressive systemic disease affects the organs throughout the body where the nodules contains collection of inflammatory cells. In majority of the cases sarcoidosis is cured within a year or two and only 30% of the sarcoidosis develop chronic disease. The market for sarcoidosis therapeutics is expected to boom due to the number of research undertaking and funding to control the rising prevalence of this disease. NIH granted USD 8.3 million to the University of Pittsburgh to explore the relationship between lung bacteria, the gene activation process and sarcoidosis disease progression. For the sarcoidosis study the Genomics and Informatics Center would collect patient clinical data from seven clinical center and use advanced microbiome and genome profiling techniques to identify biomarkers. These biomarkers would help identify the current state of lung disease and further predict its progression. Such integration of microbiome, genome and clinical information for sarcoidosis disease would dramatically change its management. Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3340 Sarcoidosis therapeutics market has been segmented on the basis of diagnosis, treatment and region. There is no blood test for diagnosis sarcoidosis. In order to negate some other infections, doctors always tests skin or lung sample during biopsy. In case where the patient chest x-ray is abnormal, bronchoscopy is performed. Small pieces of lung tissues are collected for testing. Treatment of sarcoidosis starts by limiting the initiation of granuloma formation by inhibiting antigen processing, preventing fibrosing processe, limiting inflammatory lesions causing organ interference, severe chronic fatigue, inhibiting constitutional manifestations like cough and exertional dyspnea. The number of clinical trials undertaken for sarcoidosis has increased past some years. The disease is highly undiscovered and hence offers a potential for industry players to mark their market presence. Some companies such as Auven Therapeutics have obtained rights from research universities to further carry out clinical trials on a new molecule. Auven Therapeutics obtained rights to futher develop KIACTA from the Icahn School of Medicine. The research is now carried as a collaborative effort between Auven Therapeutics and BELLUS Health. The companies are evaluating the potential use of KIACTA for the treatment of patients suffering from pulmonary sarcoidosis. They have developed a Phase2/3 protocol to evaluate the efficacy and safety of KIACTA in sarcoidosis. Geographically, sarcoidosis therapeutics market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa. North America region is projected to dominate the sarcoidosis therapeutics marketover the forecast period. The amount of research undertaken by various companies, industry academia partnership and funding to encourage more research are some of the factors contributing to North Americas lion share. Europe is the second largest region in terms of revenue share as it also has number of clinical trials ongoing. Asia Pacific is expected to be the fastest growing region for the sarcoidosistherapeutics market. The region is expected to boom owing to the prevalence rate and grants received from various international associations. A professor from National Jewish Health, received USD 40,000 per for two years from the Foundation for Sarcoidosis Research (FSR) grant /American Thoracic Society. The Foundation for Saroidosis Research (FSR) is a non-profit organization dedicated to find a cure or improve care for sarcoidosis. The foundation has awarded USD 1 million for research and additional USD 1.2 million for funding to investigators. Key Players Some of the key players in sarcoidosis therapeutics market include Bellus Helath, FirstString Research Inc., Relief Therapeutics, Araim Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, PharmaIN Corporation, Adaptimmune Therapeutics Plc, EpiZyme, Inc. and Advenchen Laboratories, LLC. Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-3340 Market Segments Based on the diagnosis, sarcoidosis therapeutics market is segmented into the following: X-ray Corticosteroids Others Changing market dynamics in the industry In-depth market segmentation Recent industry trends and developments Competitive landscape

Auven Therapeutics Investments

12 Investments

Auven Therapeutics has made 12 investments. Their latest investment was in Inozyme Pharma as part of their Series A - II on November 11, 2018.

CBI Logo

Auven Therapeutics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/9/2018

Series A - II

Inozyme Pharma

$67M

Yes

8

10/29/2018

Private Equity

Smartech Topical

$0.49M

Yes

1

10/23/2017

Series E

ADC Therapeutics

$200M

No

14

6/16/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/18/2016

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/9/2018

10/29/2018

10/23/2017

6/16/2017

10/18/2016

Round

Series A - II

Private Equity

Series E

Series A

Series D

Company

Inozyme Pharma

Smartech Topical

ADC Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$67M

$0.49M

$200M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

1

14

10

10

Auven Therapeutics Portfolio Exits

4 Portfolio Exits

Auven Therapeutics has 4 portfolio exits. Their latest portfolio exit was Inozyme Pharma on July 24, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/24/2020

IPO

$99M

4

5/19/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/2/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/15/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/24/2020

5/19/2020

11/2/2016

10/15/2013

Exit

IPO

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

Auven Therapeutics Partners & Customers

4 Partners and customers

Auven Therapeutics has 4 strategic partners and customers. Auven Therapeutics recently partnered with Bellus Health on May 5, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

5/7/2014

Partner

Bellus Health

Canada

BELLUS Health reports results for the year ended December 31, 2014

Overall proceeds from potential future revenue of KIACTA ™ will be shared between Auven Therapeutics and BELLUS Health Inc. based on a pre-agreed formula included in the agreement , and assuming that total divestiture transaction proceeds reach a pre-determined threshold , the parties will share aggregate proceeds equally .

8

5/2/2014

Licensor

Icahn School of Medicine at Mount Sinai

United States

Subscribe to see more

Subscribe to see more

10

1/10/2011

Licensor

Resolvyx Pharmaceuticals

United States

Subscribe to see more

Subscribe to see more

10

Licensee, and Licensor

Bellus Health, and Mount Sinai Health System

Canada, and United States

Subscribe to see more

Subscribe to see more

10

Date

5/7/2014

5/2/2014

1/10/2011

Type

Partner

Licensor

Licensor

Licensee, and Licensor

Business Partner

Bellus Health

Icahn School of Medicine at Mount Sinai

Resolvyx Pharmaceuticals

Bellus Health, and Mount Sinai Health System

Country

Canada

United States

United States

Canada, and United States

News Snippet

BELLUS Health reports results for the year ended December 31, 2014

Overall proceeds from potential future revenue of KIACTA ™ will be shared between Auven Therapeutics and BELLUS Health Inc. based on a pre-agreed formula included in the agreement , and assuming that total divestiture transaction proceeds reach a pre-determined threshold , the parties will share aggregate proceeds equally .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

8

10

10

10

Auven Therapeutics Team

6 Team Members

Auven Therapeutics has 6 team members, including current Founder, Managing General Partner, Stephen R. Evans-Freke.

Name

Work History

Title

Status

Peter B. Corr

Founder

Current

Stephen R. Evans-Freke

Founder, Managing General Partner

Current

Tomasz Sablinski

Managing Director

Current

Richard Warburg

Managing Director

Current

Dipal Doshi

Senior Vice President

Former

Name

Peter B. Corr

Stephen R. Evans-Freke

Tomasz Sablinski

Richard Warburg

Dipal Doshi

Work History

Title

Founder

Founder, Managing General Partner

Managing Director

Managing Director

Senior Vice President

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.